Methyltestosterone


Full Prescribing Info
Dosage/Direction for Use

Oral
Male hypogonadism
Adult: Androgen deficiency: 10-50 mg daily . Postpubertal cryptorchidism: 30 mg daily.

Oral

Menopausal vasomotor symptoms
Adult: For short term treatment: 1.25-2.5 mg daily in combination with estrogen for 21 days or 28-day cycle.

Oral

Metastatic breast carcinoma in postmenopausal women
Adult: 50-200 mg daily.

Buccal

Male hypogonadism
Adult: Androgen deficiency: 5-25 mg daily. Postpubertal cryptorchidism: 15 mg daily.

Buccal

Metastatic breast carcinoma in postmenopausal women
Adult: 25-100 daily.

Oral

Prophylaxis of postpartum breast pain and engorgement
Adult: 80 mg daily for 3-5 days after childbirth.

Buccal

Prophylaxis of postpartum breast pain and engorgement
Adult: 40 mg daily for 3-5 days after childbirth.
Contraindications
In males, known or suspected carcinoma of the breast or prostate. Pregnancy. Severe hepatic impairment.
Special Precautions
Hepatic impairment; monitor liver function periodically. Breast cancer in women; may cause hypercalcaemia. DM. Conditions influenced by oedema (e.g. CV disease, migraine, seizure disorder, renal impairment). Elderly. May accelerate bone maturation without compensatory gain in linear growth in children. Monitor for signs of virilisation in women (discontinue if mild virilisation develops) and development of priapism or excessive sexual stimulation in men. Lactation.
Adverse Reactions
Oedema; headache, anxiety, depression; acne, male-pattern baldness, seborrhoea; hypercalcaemia, hypercholesterolaemia; GI irritation, nausea, vomiting; leucopenia, polycythemia; hypersensitivity reactions. Male: Virilism, priapism, prostatic hyperplasia, prostatic carcinoma, impotence, testicular atrophy, gynaecomastia. Female: Virilism, menstrual irregularities (amenorrhoea), breast soreness, hirsutism (increase in pubic hair growth), atrophy.
Potentially Fatal: Cholestatic hepatitis with jaundice, peliosis hepatis, hepatic neoplasms.
Overdosage
Abnormal LFTs.
Drug Interactions
May increase effects of oral anticoagulants and hypoglycaemic agents.
Potentially Fatal: May increase risk of ciclosporin toxicity.
Lab Interference
May decrease thyroxine-binding globulin concentrations.
Action
Methyltestosterone is a synthetic androgenic anabolic steroid hormone. It promotes growth and development of male sex organs by stimulating receptors in organs and tissues, and maintains secondary sex characteristics in androgen-deficient men.
Absorption: Absorbed from the GI tract and from the oral mucosa.
Metabolism: Hepatic.
Excretion: Via urine.
ATC Classification
G03BA02 - methyltestosterone ; Belongs to the class of 3-oxoandrosten (4) derivative androgens used in androgenic hormone preparations.
G03EK01 - methyltestosterone ; Belongs to the class of androgens and female sex hormones in combination.
Disclaimer: This information is independently developed by CIMS based on methyltestosterone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in